FDA approves first gene therapy to treat glycogen storage disease type Ia

The FDA has granted accelerated approval of a gene therapy to treat children and adults aged at least 8 years with glycogen storage disease type Ia, according to an industry press release. Pariglasgene brecaparvovec-opnr (Genglycos, Ultragenyx) is the first therapy approved by the FDA to reduce burden of care associated with glycogen storage disease type Ia, according to the company. Glycogen